GPC Biotech AG is restructuring and will reduce its U.S. staff by 46 employees (approximately 15%) with reductions in the commercialization, drug development and general and administrative groups. The company also announced that Martine George, M.D. will succeed Marcel Rozencweig, M.D. as senior vice president, drug development and chief medical officer and will assume leadership of the company’s drug development team. Dr. Rozencweig will assume the position of senior vice president, clini...